News
Covaxin, Bharat Biotech’s Coronavirus Vaccine, Cleared For Phase 3 Trials
Covaxin, the coronavirus vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been cleared for the third phase of clinical trials.
The Hyderabad-based vaccine maker had applied to the Drugs Controller General...
Clinical Trials
Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial
The Global Coalition for Adaptive Research (GCAR) in collaboration with Amgen and Eisai Co., Ltd., announced enrollment of the first patient in the immune modulation domain of REMAP-COVID, a sub-study of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial...
Clinical Trials
AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ in Atopic Dermatitis
AbbVie at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress show that significantly more atopic dermatitis patients treated with upadacitinib (15 mg or 30 mg; once daily) monotherapy achieved improvement in additional measures of skin clearance...
Clinical Trials
Baxter Supports New Study Showing Blood Purification with Oxiris Filter Set Can Play a Role in the Management of Severely Ill COVID-19 Patients
Baxter International Inc., a global leader in acute care, recognizes the findings of a prospective, multicenter, observational study on data from the OxirisNet Registry evaluating severely ill patients with COVID-19 in Italy treated with extracorporeal (outside the body) blood...
Drug Research
Schreiner MediPharm Equips Cap-Lock Security Label with RFID Technology
Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, has enhanced its tamper-evident specialty label, Cap-Lock, with a special RFID inlay. Developed to help hospitals expand digitization initiatives, the label-and-cap security concept for...
News
Catalent to Acquire Cell Therapy Manufacturing Facility from Bone Therapeutics
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it had signed an agreement with Bone Therapeutics to acquire its cell therapy...
News
CStone signs pact to out-license ex-Greater China rights for immune checkpoint inhibitors, sugemalimab & CS1003 to EQRx
CStone Pharmaceuticals announced an agreement to out-license ex-Greater China rights for two key late-stage immuno-oncology assets, sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx, a biopharmaceutical company with an innovative business model that will allow these drugs to be competitively...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
